MannKind News

Behavioral finance theory tells us that one should not underestimate the influence of the patient population and their families in the potential success of MannKind's Afrezza.

Despite MannKind's positive developments including the company's stellar Affinity Trials' data, unanimous backing from Advisory Committees experts, and FDA approval for Afrezza, Mr. Market's persistent condemnation of MannKind continues.

According to CNBC , Tourbillon Capital's Jason Karp is betting on a decline of MannKind Corporation shares.

The issue of lung safety and lung cancer with inhaled insulin has not gone away, and should not be underestimated.

However, in all but one case, Afrezza may compete with their strongest and most profitable existing drug or with new drugs in their pipelines.

The prior day's massive insider shares purchased lend support to investor's sentiment that Mannkind would finalize potential buyout or partnership negotiation soon, and this would unlock significant value for shareholders.

MannKind VP Diane Palumbo unloaded 17,901 shares of the stock in a transaction that occurred on Tuesday, July 15th.

MannKind fell 3.4% on Thursday after an insider sold shares in the company, Analyst Ratings Net reports.

The 20 stocks listed in the table below have attracted the highest total options volume during the past 10 trading days.

Mannkind Corporation is a small company based in Valencia, California, focusing on the development and commercialization of medicine to treat diabetes.

AntriaBio's once-weekly insulin injection is in early-stage development, but as the examples used have shown, potentially disruptive drugs candidates have warranted rich valuations even at early stages.

The ideal partner would be a large, global company with a strong presence in the diabetes care niche but with no product whose sales would be threatened by a successful Afrezza.

Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin.

What's taking so long? I jest. But I'm allowed to. MannKind has been talking about a partnership since before the FDA first rejected the drug f Without a doubt, a partnership is the next big catalyst for the stock now that Afrezza is approved.

On June 27, the US Food and Drug Administration approved Afrezza, a first-in-class inhalable insulin/inhaler combination, for adults with diabetes.

MannKind CFO Matthew J. Pfeffer sold 20,000 shares of the company's stock in a transaction dated Tuesday, July 1st.

MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

MannKind COO Hakan Edstrom purchased 1,692 shares of MannKind stock in a transaction dated Monday, June 30th.

June 30, 2014 -- Millions of people with type 1 or type 2 diabetes will have another treatment option now that the FDA has approved an inhaled insulin .